Glimecaid-MP 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1 mg, Metformin 500 mg, and Pioglitazone 15 mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates gene expression involved in glucose and lipid metabolism. The combined action of these agents addresses multiple pathophysiological defects of type 2 diabetes, including impaired insulin secretion, insulin resistance, and increased hepatic glucose output. Glimecaid-MP 1 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. The sustained-release formulation allows for once-daily dosing, enhancing patient compliance. Caution is advised in patients with renal or hepatic impairment, and monitoring for hypoglycemia and other adverse effects is recommended. This combination therapy should be prescribed under medical supervision with periodic assessment of glycemic status and organ function.